TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by Scripps Clinic Cancer Center
Sponsor:
Collaborator:
Threshold Pharmaceuticals
Information provided by (Responsible Party):
Scripps Clinic Cancer Center
ClinicalTrials.gov Identifier:
NCT01721941
First received: October 8, 2012
Last updated: July 3, 2014
Last verified: July 2014
  Purpose

The primary objective of this phase I dose escalation study is to determine the maximum tolerated dose of TH-302 when administered with doxorubicin via trans-arterial chemo-embolization (TACE) in patients with hepatocellular carcinoma (HCC) who are not transplant candidates and have unresectable disease. HCC is the second leading cause of worldwide cancer death and is generally incurable without liver transplant. TACE can convert about 40% of these patients to transplant candidates. Additionally, in non-transplant HCC patients, TACE confers statistical improvements in overall survival. Selective HCC arterial catheterization during TACE allows for the delivery of concentrated drugs to the liver tumor but the optimal TACE chemotherapy regimen has not yet been determined. TH-302 is a hypoxia inducible agent that can be activated in the hypoxic environment induced by TACE.


Condition Intervention Phase
Hepatocellular Carcinoma
Drug: Phase I Dose level -1
Drug: Phase I dose level 1
Drug: Phase I Dose level 2
Drug: Phase I Dose level 3
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by Scripps Clinic Cancer Center:

Primary Outcome Measures:
  • Maximum tolerated dose of TH-302 use in TACE [ Time Frame: 33 weeks ] [ Designated as safety issue: Yes ]
    Maximum tolerated dose (MTD) of TH-302 when co-administered with doxorubicin via TACE in patients with advanced hepatocellular cancer will be assessed with a Fibonacci (3+3) dose escalation design.


Secondary Outcome Measures:
  • Objective response rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Assess overall response rate using standard RECIST criteria measured by triple phase CT or MRI at least 6 weeks post TACE administration


Estimated Enrollment: 20
Study Start Date: December 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase I dose level -1
TH-302 25mg; Doxorubicin 50mg
Drug: Phase I Dose level -1
The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Experimental: Phase I Dose level 1
TH-302 50mg; doxorubicin 50mg
Drug: Phase I dose level 1
The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Experimental: Phase I Dose level 2
TH-302 100mg; doxorubicin 50mg
Drug: Phase I Dose level 2
The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Experimental: Phase 1 Dose level 3
TH-302 150mg; Doxorubicin 50mg
Drug: Phase I Dose level 3
The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).

Detailed Description:

Transarterial chemoembolization (TACE) is the major modality utilized for tumor downstaging for transplant and for local therapy in non-transplant patients. This procedure allows delivery of concentrated drugs to the tumor, followed by embolization that eliminates its blood supply creating an environment of hypoxia. The process induces tumor ischemia, while achieving a drug concentration in the tumor 10 to 25 times greater than can be achieved by infusion.

A hypoxic microenvironment is a characteristic of many solid tumors including hepatocellular cancer, further induced by TACE. The hypoxia-activated prodrug, TH-302, is designed to selectively physiologically target the hypoxic microenvironment. While doxorubicin and cisplatin have been used as the drugs in TACE among other agents, none have stood out as the optimal agent in targeting HCC. Because of the action of TH-302 in hypoxia, this agent has a mechanistic advantage as a agent in TACE.

The current study is designed to assess the potential therapeutic benefit of adding TH-302 to the standard doxorubicin based TACE regimen in patients with advanced hepatocellular carcinomas.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age
  • Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee
  • Patients with hepatocellular carcinoma with either:

    1. liver limited disease who are not transplant candidates as they fall outside of Milan criteria, but may be eligible for transplant after successful downstaging with TACE
    2. liver limited disease who satisfy Milan criteria, but are at risk of falling out of Milan criteria before they receive a liver transplant
    3. non-transplantable HCC but with liver limited or metastatic disease that requires local TACE therapy
  • Measurable disease by modified RECIST criteria (at least one target lesion outside of previous radiation fields)
  • ECOG performance status of 2 or less
  • Life expectancy of at least 3 months
  • Childs-Pugh Class A or B
  • HCC amenable to TACE
  • Patent main portal vein (thrombosis of portal vein branch not exclusionary)
  • Acceptable liver function:
  • Bilirubin < 2 mg/dL
  • AST (SGOT) and ALT (SGPT) < 5 x ULN is allowed
  • Acceptable renal function:
  • Serum creatinine < 1.5 ULN
  • Acceptable hematologic status (without hematologic support for TACE #1):
  • ANC > 500 cells/μL
  • Platelet count > 50,000/μL

Exclusion Criteria:

  • New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
  • Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for >=3 months)
  • Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
  • Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation <90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Sorafenib within the previous 4 weeks or the intention to initiate sorafenib while on study
  • Poor liver function as indicated by serum bilirubin > 2 mg/dL, Child-Pugh Class C, severe coagulopathy (INR > 2) not correctable with vitamin K, or active hepatic encephalopathy
  • Main portal vein occlusion
  • Liver rupture or tumor penetration of liver capsule
  • Tumor invasion of biliary system with biliary obstruction
  • Severe cytopenias, including ANC < 500 cells/μL, Hemoglobin < 8 g/dL, or platelets < 50,000/μL
  • Subjects who have exhibited allergic reactions to a structural compound, biological agent similar to TH-302
  • Females who are pregnant or breast-feeding
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  • Unwillingness or inability to comply with the study protocol for any reason
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01721941

Contacts
Contact: Alain Perez 858-554-9379 Perez.Alain@scrippshealth.org

Locations
United States, California
Scripps Clinic Not yet recruiting
La Jolla, California, United States, 92037
Contact: Alain Perez    858-554-8937    Perez.Alain@scrippshealth.org   
Principal Investigator: Darren S Sigal, M.D.         
Sponsors and Collaborators
Scripps Clinic Cancer Center
Threshold Pharmaceuticals
Investigators
Principal Investigator: Darren S Sigal, MD Scripps Health
  More Information

No publications provided

Responsible Party: Scripps Clinic Cancer Center
ClinicalTrials.gov Identifier: NCT01721941     History of Changes
Other Study ID Numbers: TH302 TACE
Study First Received: October 8, 2012
Last Updated: July 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Scripps Clinic Cancer Center:
hepatocellular carcinoma
HCC
liver cancer
hepatoma
TACE
transarterial chemoembolization
TH302

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 31, 2014